Moroccan coach Rachid Taoussi hospitalized with Malaria in Tanzania
Moroccan coach Rachid Taoussi, head coach of Azam FC in Tanzania, has been admitted to the intensive care unit of a hospital in Dar es Salaam after contracting malaria, a disease prevalent in East Africa.
According to medical sources, Taoussi has passed the critical stage and his condition is gradually improving, though he remains under medical supervision until he fully recovers.
He is expected to be discharged in the coming days, provided his condition continues to stabilize.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Ya Biladi
16 hours ago
- Ya Biladi
Mohammed VI Foundation and AstraZeneca partner to enhance rare disease care in Morocco
The Mohammed VI Foundation for Science and Health (FM6SS) and AstraZeneca signed a memorandum of understanding on Wednesday in Rabat to jointly develop Centers of Excellence for rare diseases, aiming to strengthen Morocco's healthcare ecosystem and improve care for patients affected by these conditions. This partnership is part of a broader initiative to provide innovative solutions to patients by facilitating earlier diagnosis, improving access to treatment, and enhancing training for healthcare professionals. It includes the development of advanced diagnostic platforms, the integration of cutting-edge technologies in genetic testing, and the creation of multidisciplinary hubs for care, research, and education. In a statement to MAP, Saber Boutayeb, Director of the Mohammed VI Center for Research and Innovation, said the agreement marks the culmination of a collaborative effort with AstraZeneca at the regional level, extending beyond Morocco. Rami Scandar, AstraZeneca's Regional President for the Near East and Maghreb, emphasized that the partnership is built around five key pillars. The first is reducing the average diagnostic time for rare diseases, which can currently take up to five years, thereby improving patient outcomes. The second involves creating genetic testing platforms in collaboration with the Foundation. The third pillar focuses on training doctors, nurses, and caregivers to strengthen support for patients with rare conditions. The fourth addresses equitable access to treatment by introducing medications priced appropriately for the Moroccan context, in coordination with the Ministry of Health. Finally, the fifth pillar seeks to improve epidemiological knowledge of rare diseases in Morocco through data collection and scientific monitoring. This agreement further reinforces AstraZeneca's long-term commitment to sustainable growth and partnership in Morocco. Building on previous successful collaborations with the Mohammed VI Foundation for Science and Health, the two parties are charting a shared path to address unmet medical needs and deliver a lasting, tangible impact for patients across the Kingdom.
Morocco World
19 hours ago
- Morocco World
Sothema Acquires Soludia Maghreb in MAD 1 Billion Deal
Marrakech – Pharmaceutical group Sothema, led by CEO Lamia Tazi, has finalized an agreement to acquire 99.99% of Soludia Maghreb's capital, valued at nearly MAD 1 billion ($100 million). The deal was reached with Soludia's historical shareholders: Abdelaziz Razkaoui, Cap Mezzanine III fund managed by CDG Invest Growth, and the Zine family. Founded in 1996, Soludia Maghreb has established itself as a leading industrial player in hemodialysis in Morocco. The company manufactures essential hemodialysis products, including powdered bicarbonate cartridges and liquid acid and bicarbonate solutions. Soludia also distributes pharmaceutical specialties for international partners and holds 40% of Hidropura Maroc, a company specializing in the installation and maintenance of acid plants and water treatment systems for hemodialysis centers. According to 2025 projections, Soludia is expected to generate revenue of MAD 360 million ($36 million) and an adjusted EBITDA of MAD 90 million ($9 million), excluding post-acquisition synergies. An additional price of MAD 95 million ($9.5 million) may be paid, contingent on meeting specific financial objectives. As part of the agreement, Abdelaziz Razkaoui will continue to serve as Soludia's CEO for a minimum period of five years, ensuring management continuity. Razkaoui and CDG Invest Growth chose to convert 80% of their shares in Soludia into Sothema shares instead of opting for a cash payment – a move that reflects their confidence in the group's long-term vision and leadership. The remaining cash payment amounts to approximately MAD 365 million ($36.5 million). Sothema has confirmed that no capital increase will be necessary to finance this transaction. A bold advance in Sothema's industrial strategy With this acquisition, Sothema estimates its 2025 consolidated revenue at about MAD 3.5 billion ($350 million) and consolidated EBITDA exceeding MAD 800 million ($80 million). This strategic acquisition represents a bold advance in Sothema's industrial strategy, reinforcing its therapeutic portfolio in a sector regarded as critical to public health, according to their press release. The deal aims to enhance national industrial capabilities in hemodialysis, expand Sothema's therapeutic portfolio in a segment with high public health impact, and increase Soludia's competitiveness in international markets, particularly in West Africa and the Middle East. Established in 1976, Sothema is a key player in the Moroccan pharmaceutical industry. The group has partnerships with around forty leading international R&D laboratories and develops its own ranges of generics, biosimilars, and medical devices, with an extensive presence across Africa and the Arab world. The completion of the transaction remains subject to the fulfillment of customary closing conditions, particularly approval from the Competition Council. The closing is expected before the end of 2025. Tags: pharmaceutical industry in MoroccoSothema
Morocco World
a day ago
- Morocco World
Real Madrid Reconsiders Ouazane Transfer After Dutch Medical Clears Moroccan Teen
Real Madrid may reignite talks to sign Moroccan teenager Abdellah Ouazane after new medical tests contradicted earlier concerns that had stalled the deal. According to Dutch newspaper De Telegraaf , a full examination carried out at Amsterdam's University Medical Centre (UMC) found no health issues and deemed the 17-year-old 'fully fit for top-level sport'. The findings challenge the initial assessment from Madrid's medical team, which raised unspecified red flags and led to the transfer being put on hold at the last minute. Ouazane, one of Morocco's standout players at the last U17 Africa Cup of Nations, was on the brink of joining the Spanish giants when the move collapsed. While Ajax, his current club, has offered him a spot in the reserves for now, the fresh diagnosis could open new opportunities. Other European clubs are reportedly monitoring the situation. If Madrid is satisfied with the Dutch report, negotiations could resume. If not, Ouazane is unlikely to be short of offers. Tags: Abdellah OuazaneAjax AmsterdamReal Madrid
